-transparent.png){kind=logo}
During the screening of novel platelet-activating factor (PAF) antagonists, we found that 1-(6-methoxy-3,4-dihydro-2-naphthoyl)-4- (3,4,5-trimethoxybenzyl)piperazine and its 4-(3,4,5- trimethoxybenzoyl)piperazine derivatives (1b, 2b) exerted in vitro and in vivo PAF-antagonistic activities. Modifications of the 1-acyl group, the substituent at the 4-position and the piperazine ring of 1a and 2b were examined and from this series 1-(2,3-dimethoxy-6,7-dihydro-5H-benzocyclohepten-8-ylcarbonyl++ +)-4- (3,4,5-trimethoxybenzoyl)piperazine (2g) was found to be one of the most potent PAF antagonists.
Related Publications
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
January 1991,
Journal of lipid mediators,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
May 1996,
Journal of lipid mediators and cell signalling,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
September 1989,
Chemical & pharmaceutical bulletin,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
July 1986,
Bioorganicheskaia khimiia,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
May 1995,
Die Pharmazie,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
January 1987,
British journal of pharmacology,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
August 2010,
European journal of medicinal chemistry,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
February 1992,
Journal of lipid mediators,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
June 1984,
Chemical & pharmaceutical bulletin,
H Fukushi, and
H Mabuchi, and
K Itoh, and
Z Terashita, and
K Nishikawa, and
H Sugihara
January 1989,
Journal of lipid mediators,
